News Articles Tagged: OAB Drug Development

Imidafenacin (CAS 170105-16-5): A Strategic Chemical for OAB Drug Development

Learn why Imidafenacin (CAS 170105-16-5) is vital for OAB drug development. Discover sourcing strategies and partner with a reliable manufacturer for your research needs.

The Pharmaceutical Journey of Vibegron: From Discovery to OAB Treatment

NINGBO INNO PHARMCHEM CO.,LTD. looks at the development of Vibegron, a selective beta-3 adrenergic receptor agonist for Overactive Bladder, covering its scientific basis, clinical journey, and API significance.

Solifenacin Succinate: A Key Player in Managing Overactive Bladder and Urinary Incontinence

An in-depth look at Solifenacin Succinate (CAS 242478-38-2), its role in treating overactive bladder symptoms, including urinary urgency and incontinence. Discusses quality, sourcing, and its significance as a pharmaceutical intermediate.